Composition :

Entecavir 0.5mg & 1mg Tablet.

Indications : This tablet is indicated for the treatment of chronic hepatitis B virus infection in adults with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases or histologically active disease.

Dosage and administration : The recommended dose of Entecavir for chronic hepatitis B virus infection in nucleoside-treatment-naive adults and adolescents 16 years of age and older is 0.5mg once daily. The recommended dose of Entecavir in adults and adolescents (>16 years of age) with a history of hepatitis B viremia while receiving lamivudine is 1mg once daily. Entecavir should be administered on an empty stomach (at least 2 hours after a meal and 2 hours before the next meal). Or, as directed by the registered physician.

Contraindication : It is contraindicated in patients with known hypersensitivity to any component of this drug.

Side effects : The most common side effects of Entecavir treated patients were headache, fatigue, dizziness and nausea.

Precautions : Renal Impairment : Dosage adjustment of Entecavir is recommended for patients with a creatinine clearance<50ml/min, including patients on hemodialysis. Hepatic Impairment : No dosage adjustment is necessary for patients with hepatic impairment.

Entavir Tablet

Pregnancy and lactation : Entecavir should be used during pregnancy only if clearly needed and after careful consideration of the risks and benefits. It is not known whether this drug is excreted in human milk. Mothers should be instructed not to breast-feed if they are taking Entecavir.

Drug interactions : Coadministered drug were not altered in interaction studies of Entecavir with lamivudine, adefovir dipivoxil, and tenofovir disoproxil fumarate.

Packing :

Entavir-0.5 : 1x14's tablets in blister pack.

Entavir-1: 1x14's tablets in blister pack.